

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PREScriBER

Name: Name:

Ward: NHI:

Inotuzumab ozogamicin

INITIATION

Re-assessment required after 4 months

Prerequisites (tick boxes where appropriate)

- Patient has relapsed or refractory CD22-positive B-cell acute lymphoblastic leukaemia/lymphoma, including minimal residual disease
- and
- Patient has ECOG performance status of 0-2
- and

 - Patient has Philadelphia chromosome positive B-Cell ALL
 - and
 - Patient has previously received a tyrosine kinase inhibitor

- or
- Patient has received one prior line of treatment involving intensive chemotherapy
- and
- Treatment is to be administered for a maximum of 3 cycles

CONTINUATION

Re-assessment required after 4 months

Prerequisites (tick boxes where appropriate)

- Patient is not proceeding to a stem cell transplant
- and

 - Patient has experienced complete disease response
 - or
 - Patient has experienced complete remission with incomplete haematological recovery

- and
- Treatment with inotuzumab ozogamicin is to cease after a total duration of 6 cycles

I confirm that the above details are correct:

Signed: Date: